

10/539451

JC20 Rec'd PCTO 20 JUN 2005

The International Bureau of WIPO
34, Chemin des Colombettes
1211 Geneva 20
SWITZERLAND

11 April 2003

LETTER ACCOMPANYING ARTICLE 19 AMENDMENT

Dear Sirs

International Patent Application No PCT/GB02/05842
Applicant: Cancer Research Technology Limited
Our Ref: WJW/BP6109805

The International Search Report was mailed on 02 April 2003.

Filed herewith are:

- (a) replacement page 115, on which appears amended claim 1 (1 page).
- (b) Statement under Article 19(1) (1 page).

Claim 1 has been amended.

Amended claim 1 differs from original claim 1 in only one respect: the chemical formula has been corrected to be identical to that shown in the description at page 6, line 7. Amended claim 1 now precisely corresponds to the description at page 6, lines 5-26.

It is clear that there is an error in original claim 1. Claim 1 includes, at lines 12-14, references to "the bond marked β ". However, the formula in original claim 1 does not have a bond marked β .

It is clear what the error is: the annular bond "across" from the bond marked α is incorrectly shown to be a double bond in original claim 1. Original claims 2 and 4 (which depend from claim 1) require an annular double bond "across" from the bond marked α . Original claim 3 (which also depends from claim 1) requires an annular single bond "across" from the bond marked α .

It is clear what the correction must be: the bond "across" from the bond marked α must be defined as a single bond or a double bond (which is precisely what is given on page 6 of the description). The correction is achieved by replacing the chemical formula in original claim 1 with the chemical formula appearing on page 6 of the description.

Yours faithfully

Robert J Watson
APPOINTED AGENT


Encs. Replacement page 115, on which appears amended claim 1 (1 page).
Statement under Article 19(1) (1 page).

WJW/wjw
W:\WORK\WJW\CRCT\6109805 - Stevens - Quinolins No. 2 - PCT\WIPO-001-Art 19 Amend.doc

- 115 -

CLAIMS

1. A compound having the following formula:



wherein:

- 5 Ar is a 1-(sulfonyl)-1H-indol-2-yl group;
the group -OR^O is independently:

- (a) -OH;
(b) an ether group; or:
(c) an acyloxy group;

- 10 the bond marked α is independently:

- (a) a single bond; or:
(b) a double bond;

the bond marked β is independently:

- (a) a single bond; or:
(b) a double bond;

15 each of R², R³, R⁵, and R⁶, is independently a ring substituent and is:

- (a) H;
(b) a monovalent monodentate substituent; or:
(c) a ring substituent which, together with an adjacent ring

- 20 substituent, and together with the ring atoms to which these ring
substituents are attached, form a fused ring;

and pharmaceutically acceptable salts, esters, amides, solvates,
hydrates, and protected forms thereof.

25

* * *

STATEMENT UNDER ARTICLE 19(1)

International Patent Application No PCT/GB02/05842

International Filing Date: 20 December 2002

Applicant: Cancer Research Technology Limited

Claim 1 has been amended.

Amended claim 1 differs from original claim 1 in only one respect: the chemical formula has been corrected to be identical to that shown in the description at page 6, line 7. Amended claim 1 now precisely corresponds to the description at page 6, lines 5-26.

It is clear that there is an error in original claim 1. Claim 1 includes, at lines 12-14, references to "the bond marked β ". However, the formula in original claim 1 does not have a bond marked β .

It is clear what the error is: the annular bond "across" from the bond marked α is incorrectly shown to be a double bond in original claim 1. Original claims 2 and 4 (which depend from claim 1) require an annular double bond "across" from the bond marked α . Original claim 3 (which also depends from claim 1) requires an annular single bond "across" from the bond marked α .

It is clear what the correction must be: the bond "across" from the bond marked α must be defined as a single bond or a double bond (which is precisely what is given on page 6 of the description). The correction is achieved by replacing the chemical formula in original claim 1 with the chemical formula appearing on page 6 of the description.